A Phase II, open-label study evaluating pazopanib in patients with recurrent ovarian cancer

Gynecologic Oncology

Volumn 119, Issue 1, 2010, Pages 32-37

  Friedlander, Michael ^a   Hancock, Kenneth C ^b   Rischin, Danny ^c   Messing, Mark J ^b   Stringer, Claude A ^b   Matthys, Gemma M ^d   Ma, Bo ^d   Hodge, Jeffrey P ^d   Lager, Joanne J ^d  

^a PRINCE OF WALES HOSPITAL   (Australia)

^b TEXAS ONCOLOGY   (United States)

^c MERCY HOSPITAL FOR WOMEN   (Australia)

^d GLAXOSMITHKLINE   (United States)

Author keywords

CA 125; Ovarian cancer; Pazopanib

Indexed keywords

CA 125 ANTIGEN; PAZOPANIB; UNCLASSIFIED DRUG; VOTRIENT; PYRIMIDINE DERIVATIVE; SULFONAMIDE;

ADULT; AGED; ALANINE AMINOTRANSFERASE BLOOD LEVEL; ANEMIA; ARTICLE; ASPARTATE AMINOTRANSFERASE BLOOD LEVEL; BLEEDING; BLOOD CLOTTING DISORDER; CANCER CHEMOTHERAPY; CANCER STAGING; CLINICAL ARTICLE; CLINICAL TRIAL; DIARRHEA; DRUG DOSE REDUCTION; DRUG EFFICACY; DRUG SAFETY; DRUG SCREENING; DRUG WITHDRAWAL; FATIGUE; FEMALE; HEPATOBILIARY TOXICITY; HUMAN; HYPERTENSION; HYPOALBUMINEMIA; MONOTHERAPY; MULTICENTER STUDY; NAUSEA; NEUTROPENIA; OVARY CANCER; PERIPHERAL EDEMA; PHASE 2 CLINICAL TRIAL; PRIORITY JOURNAL; PROTEINURIA; RECURRENT CANCER; SIDE EFFECT; THROMBOCYTOPENIA; THROMBOSIS; TREATMENT RESPONSE; BLOOD; DISEASE FREE SURVIVAL; FALLOPIAN TUBE NEOPLASMS; MIDDLE AGED; NEOPLASM RECURRENCE, LOCAL; OVARIAN NEOPLASMS; PERITONEAL NEOPLASMS; SURVIVAL RATE; VERY ELDERLY;

ADULT; AGED; AGED, 80 AND OVER; CA-125 ANTIGEN; DISEASE-FREE SURVIVAL; FALLOPIAN TUBE NEOPLASMS; FEMALE; HUMANS; MIDDLE AGED; NEOPLASM RECURRENCE, LOCAL; OVARIAN NEOPLASMS; PERITONEAL NEOPLASMS; PYRIMIDINES; SULFONAMIDES; SURVIVAL RATE;

EID: 77956649079     PISSN: 00908258     EISSN: 10956859     Source Type: Journal    
DOI: 10.1016/j.ygyno.2010.05.033     Document Type: Article

References (42)

1. A. Jemal, R. Siegel, and E. Ward Cancer statistics, 2008 CA Cancer J Clin 58 2008 71 96
2. J. Engel, R. Eckel, and G. Schubert-Fritschle Moderate progress for ovarian cancer in the last 20 years: prolongation of survival, but no improvement in the cure rate Eur J Cancer 38 2002 2435 2445
3. J.P. Neijt, S.A. Engelholm, and M.K. Tuxen Exploratory phase III study of paclitaxel and cisplatin versus paclitaxel and carboplatin in advanced ovarian cancer J Clin Oncol 18 2000 3084 3092
4. R.F. Ozols, B.N. Bundy, and B.E. Greer Phase III trial of carboplatin and paclitaxel compared with cisplatin and paclitaxel in patients with optimally resected stage III ovarian cancer: a Gynecologic Oncology Group study J Clin Oncol 21 2003 3194 3200
5. R.E. Bristow, R.S. Tomacruz, D.K. Armstrong, E.L. Trimble, and F.J. Montz Survival effect of maximal cytoreductive surgery for advanced ovarian carcinoma during the platinum era: a meta-analysis J Clin Oncol 20 2002 1248 1259
6. A. du Bois, J.P. Neijt, and J.T. Thigpen First line chemotherapy with carboplatin plus paclitaxel in advanced ovarian cancer-a new standard of care? Ann Oncol 10 suppl 1 1999 35 41
7. R.J. Morgan Jr., R.D. Alvarez, and D.K. Armstrong Ovarian cancer. Clinical practice guidelines in oncology J Natl Compr Canc Netw 6 2008 766 794
8. T.J. Herzog, and B. Pothuri Ovarian cancer: a focus on management of recurrent disease Nat Clin Pract Oncol 3 2006 604 611
9. R.E. Bristow, I. Puri, and D.S. Chi Cytoreductive surgery for recurrent ovarian cancer: a meta-analysis Gynecol Oncol 112 2009 265 274
10. G.J. Rustin, P. Timmers, and A. Nelstrop Comparison of CA-125 and standard definitions of progression of ovarian cancer in the intergroup trial of cisplatin and paclitaxel versus cisplatin and cyclophosphamide J Clin Oncol 24 2006 45 51
11. S. Aebi, and M. Castiglione Epithelial ovarian carcinoma: ESMO clinical recommendations for diagnosis, treatment and follow-up Ann Oncol 19 suppl 2 2008 ii14 ii16
12. G.J.S. Rustin Use of CA-125 to assess response to new agents in ovarian cancer trials J Clin Oncol 21 10 suppl 2003 187s 193s
13. I. Vergote, G.J. Rustin, and E.A. Eisenhauer Re: new guidelines to evaluate the response to treatment in solid tumors [ovarian cancer]. Gynecologic Cancer Intergroup J Natl Cancer Inst 92 2000 1534 1535
14. G.J. Rustin, M.E. van der Burg on behalf of MRC and EORTC collaborators A randomized trial in ovarian cancer (OC) of early treatment of relapse based on CA125 level alone versus delayed treatment based on conventional clinical indicators (MRC OV05/EORTC 55955 trials) J Clin Oncol 27 2009 (15S Part I of II):5s (abstr #1)
15. D.K. Armstrong Relapsed ovarian cancer: challenges and management strategies for a chronic disease Oncologist 7 suppl 5 2002 20 28
16. M.R. Raspollini, F. Castiglione, and F. Garbini Correlation of epidermal growth factor receptor expression with tumor microdensity vessels and with vascular endothelial growth factor expression in ovarian carcinoma Int J Surg Pathol 13 2005 135 142
17. B.C. Cooper, J.M. Ritchie, and C.L. Broghammer Preoperative serum vascular endothelial growth factor levels: significance in ovarian cancer Clin Cancer Res 8 2002 3193 3197
18. S. Yamamoto, I. Konishi, and M. Mandai Expression of vascular endothelial growth factor (VEGF) in epithelial ovarian neoplasms: correlation with clinicopathology and patient survival, and analysis of serum VEGF levels Br J Cancer 76 1997 1221 1227
19. C.A. Chen, W.F. Cheng, and C.N. Lee Serum vascular endothelial growth factor in epithelial ovarian neoplasms: correlation with patient survival Gynecol Oncol 74 1999 235 240
20. K.A. Suhonen, M.A. Anttila, and S.M. Sillanpaa Quantification of angiogenesis by the Chalkley method and its prognostic significance in epithelial ovarian cancer Eur J Cancer 43 2007 1300 1307
21. K. El-Shami, A. Elsaid, and Y. El-Kerm Open-label safety and efficacy pilot trial of intraperitoneal bevacizumab as palliative treatment in refractory malignant ascites J Clin Oncol 25 2007 (18S Part I of II):503s (abstr #9043)
22. S. Mesiano, N. Ferrara, and R.B. Jaffe Role of vascular endothelial growth factor in ovarian cancer: inhibition of ascites formation by immunoneutralization Am J Pathol 153 1998 1249 1256
23. U.S. Department of Health and Human Services Food & Drug Administration. Pazopanib [approval notice], published 2009. (http://www.fda.gov/AboutFDA/CentersOffices/CDER/ucm187509.htm ).
24. G. Sonpavde, and T.E. Hutson Pazopanib: a novel multitargeted tyrosine kinase inhibitor Curr Oncol Rep 9 2007 115 119
25. H.I. Hurwitz, A. Dowlati, and S. Saini Phase I trial of pazopanib in patients with advanced cancer Clin Cancer Res 15 2009 4220 4227
26. S.J. Green, and S. Dahlberg Planned versus attained design in phase II clinical trials Stat Med 11 1992 853 862
27. G.J. Rustin, M. Quinn, and T. Thigpen Re: New guidelines to evaluate the response to treatment in solid tumors (ovarian cancer) J Natl Cancer Inst 96 2004 487 488
28. P. Therasse, S.G. Arbuck, and E.A. Eisenhauer New guidelines to evaluate the response to treatment in solid tumors. European Organization for Research and Treatment of Cancer, National Cancer Institute of the United States, National Cancer Institute of Canada J Natl Cancer Inst 92 2000 205 216
29. Cancer Therapy Evaluation Program. Common Terminology Criteria for Adverse Events v3.0 (CTCAE), published August 2006. (http://ctep.cancer.gov/ protocolDevelopment/electronic-applications/docs/ctcaev3.pdf ).
30. R.A. Burger, M.W. Sill, B.J. Monk, B.E. Greer, and J.I. Sorosky Phase II trial of bevacizumab in persistent or recurrent epithelial ovarian cancer or primary peritoneal cancer: a Gynecologic Oncology Group Study J Clin Oncol 25 2007 5165 5171
31. S.A. Cannistra, U.A. Matulonis, and R.T. Penson Phase II study of bevacizumab in patients with platinum-resistant ovarian cancer or peritoneal serous cancer J Clin Oncol 25 2007 5180 5186
32. A.A. Garcia, H. Hirte, and G. Fleming Phase II clinical trial of bevacizumab and low-dose metronomic oral cyclophosphamide in recurrent ovarian cancer: a trial of the California, Chicago, and Princess Margaret Hospital phase II consortia J Clin Oncol 26 2008 76 82
33. H.S. Nimeiri, A.M. Oza, and R.J. Morgan Efficacy and safety of bevacizumab plus erlotinib for patients with recurrent ovarian, primary peritoneal, and fallopian tube cancer: a trial of the Chicago, PMH, and California Phase II Consortia Gynecol Oncol 110 2008 49 55
34. B. Escudier, T. Eisen, and W.M. Stadler Sorafenib in advanced clear-cell renal-cell carcinoma N Engl J Med 356 2007 125 134
35. R.J. Motzer, T.E. Hutson, and P. Tomczak Sunitinib versus interferon alfa in metastatic renal-cell carcinoma N Engl J Med 356 2007 115 124
36. E. Pujade-Lauraine, S. Mahner, and J. Kaern A randomized, phase III study of carboplatin and pegylated liposomal doxorubicin versus carboplatin and paclitaxel in relapsed platinum-sensitive ovarian cancer (OC): CALYPSO study of the Gynecologic Cancer Intergroup (GCIG) J Clin Oncol 27 2009 (15S Part I of II):279s (abstr #LBA5509)
37. N.S. Azad, C.M. Annunziata, and S.M. Steinberg Lack of reliability of CA125 response criteria with anti-VEGF molecularly targeted therapy Cancer 112 2008 1726 1732
38. M. Markman Lack of reliability of CA125 response criteria with anti-VEGF molecularly targeted therapy [letter] Cancer 113 2008 2832 2833
39. B. Escudier, A. Pluzanska, and P. Koralewski Bevacizumab plus interferon alfa-2a for treatment of metastatic renal cell carcinoma: a randomised, double-blind phase III trial Lancet 370 2007 2103 2111
40. H. Hurwitz, L. Fehrenbacher, and W. Novotny Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer N Engl J Med 350 2004 2335 2342
41. A. Sandler, R. Gray, and M.C. Perry Paclitaxel-carboplatin alone or with bevacizumab for non-small-cell lung cancer N Engl J Med 355 2006 2542 2550
42. U.A. Matulonis, S. Berlin, and P. Ivy Cediranib, an oral inhibitor of vascular endothelial growth factor receptor kinases, is an active drug in recurrent epithelial ovarian, fallopian tube, and peritoneal cancer J Clin Oncol 27 2009 5601 5606